hikma cascara s.c. tab tablet
hikma pharmaceuticals plc - cascara sagrada extract - tablet - 325 mg
hikma midazolam 5mg-1ml ampoules solution for injection
hikma pharmaceuticals plc - midazolam - solution for injection - 5 mg/ml
colistin hikma 1.000.000 iu vial
شركة أدوية الحكمة - hikma pharmaceuticals - colistimethate 1.000.000 iu - 1.000.000 iu
colistin hikma 1.000.000 iu vial
شركة أدوية الحكمة - hikma pharmaceuticals - colistimethate 1.000.000 iu - 1.000.000 iu
vancomycin hikma powder for solution for injection/infusion
hikma pharmaceuticals ltd 182400 amman 11118 - vancomycin hydrochloride - powder for solution for injection/infusion - vancomycin hydrochloride 500mg vial - antibacterials for systemic use:
amiodaron hcl hikma 50 mg/ml, injektionslösung
levocarnitine injection
hikma pharmaceuticals usa inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. none known.
fluphenazine decanoate injection
hikma pharmaceuticals usa inc. - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate 25 mg in 1 ml - fluphenazine decanoate injection, usp is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). fluphenazine decanoate injection, usp has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.
lidocaine- lidocaine hydrochloride injection, solution lidocaine- lidocaine hydrochloride injection, solution
hikma pharmaceuticals usa inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride 10 mg in 1 ml - lidocaine hcl injections are indicated for production of local anesthesia by infiltration techniques such as percutaneous injection and by peripheral nerve block techniques such as brachial plexus and intercostal, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
leucovorin calcium injection, powder, lyophilized, for solution
hikma pharmaceuticals usa inc. - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 50 mg in 5 ml - leucovorin calcium, usp rescue is indicated after high dose methotrexate therapy in osteosarcoma. leucovorin calcium, usp is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium, usp is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin calcium, usp is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.